fostemsavir (Rukobia)
Jump to navigation
Jump to search
Indications
- treatment-resistant HIV1 infection
Dosage
- 600 mg q12 hours
Adverse effects
- nausea (most common)
- elevations in serum transaminases among patients with hepatitis B or hepatitis C
- immune reconstitution syndrome
Mechanism of action
- prodrug of temsavir
- HIV1 glycoprotein 120 (gp120) attachment inhibitor
More general terms
References
- ↑ FDA NEWS RELEASE. July 02, 2020 FDA Approves New HIV Treatment for Patients With Limited Treatment Options. https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options
- ↑ Kozal M, Aberg J, Pialoux G et al Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020 Mar 26;382(13):1232-1243. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32212519 Clinical Trial.